Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Maintains Deuruxolitinib Breakthrough Therapy Designation from FDA for the Treatment of Alopecia Areata
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Concert Pharmaceuticals Announces Presentation of Deuruxolitinib THRIVE-AA1 Phase 3 Study Results in Alopecia Areata During World Congress for Hair Research
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Concert Pharmaceuticals Reports Third Quarter 2022 Financial Results
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Concert Pharmaceuticals to Report Third Quarter 2022 Results on November 7, 2022
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Concert Pharmaceuticals Announces Presentation of CTP-543 THRIVE-AA1 Phase 3 Data in Alopecia Areata During Late Breaking Session at EADV Congress
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Concert Pharmaceuticals to Present at H.C. Wainwright Global Investment Conference
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Bridges and Landmarks Across the USA Will Illuminate Blue Throughout the Month of September for Alopecia Areata
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Concert Pharmaceuticals Announces That Results From CTP-543 THRIVE‑AA1 Phase 3 Trial in Patients With Alopecia Areata Selected for Late Breaking Presentation at EADV Congress
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Concert Pharmaceuticals Announces Exercise of Warrants Under Existing Financing Arrangement
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Concert Pharmaceuticals Reports Second Quarter 2022 Financial Results
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Concert Pharmaceuticals Reports Positive Topline Results for Second CTP‑543 Phase 3 Clinical Trial in Alopecia Areata
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Concert Pharmaceuticals to Report Second Quarter 2022 Results on August 4, 2022
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Concert Pharmaceuticals to Participate in Fireside Chat at The JMP Securities Life Sciences Conference
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Phase 2 Dose‑Ranging Clinical Trial Results of CTP‑543 in Patients with Alopecia Areata published in the Journal of the American Academy of Dermatology
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Concert Pharmaceuticals Raises Gross Proceeds of $66.4 Million Through Public Offering and Exercise of Warrants
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Concert Pharmaceuticals Announces Pricing of Public Offering
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Concert Pharmaceuticals Announces Proposed Public Offering of Common Stock
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Concert Pharmaceuticals Reports First Quarter 2022 Financial Results
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Concert Pharmaceuticals to Report First Quarter 2022 Results on May 5, 2022
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Concert Pharmaceuticals to Report Fourth Quarter 2021 Results on March 3, 2022
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Concert Pharmaceuticals Completes Enrollment in THRIVE-AA2 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Concert Pharmaceuticals to Present at H.C. Wainwright BIOCONNECT Virtual Conference
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Concert Pharmaceuticals to Participate in Fireside Chat at Jefferies London Healthcare Conferences
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Concert Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Company Update
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Concert Pharmaceuticals Announces $65 Million Financing
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Concert Pharmaceuticals to Report Third Quarter 2021 Results on November 9, 2021
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Concert Pharmaceuticals Completes Enrollment in THRIVE-AA1 Phase 3 Clinical Trial Evaluating CTP-543 for Alopecia Areata
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Concert Pharmaceuticals to Present at Upcoming Investor Conferences
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Landmarks and Bridges Will Illuminate Blue Throughout the Month of September for Alopecia Areata Awareness Month
From Concert Pharmaceuticals, Inc.
Via Business Wire
Tickers CNCE
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.